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Background: Hereditary Haemorrhagic Telangiectasia (HHT) is an autosomal dominant disease associated with
epistaxis, arteriovenous malformations and telangiectasias. Disease complications may result in premature death.
Method: We investigated life-expectancies of parents of HHT patients compared with their non-HHT partners using
self- or telephone-administered questionnaires sent to their children. Patients were extracted from the databases of
2 participating HHT Centres: the Toronto HHT Database (Toronto, Canada) and the St. Antonius Hospital HHT
Database (Nieuwegein, The Netherlands).
Results: Two hundred twenty five/407 (55 %) of respondents were included creating HHT- (n = 225) and control
groups (n = 225) of equal size. Two hundred thirteen/225 (95 %) of the HHT group had not been screened for
organ involvement of the disease prior to death. The life expectancy in parents with HHT was slightly lower
compared to parents without (median age at death 73.3 years in patients versus 76.6 years in controls, p0.018).
Parents with ACVRL 1 mutations had normal life expectancies, whereas parents with Endoglin mutations died
7.1 years earlier than controls (p = 0.024). Women with Endoglin mutations lived a median of 9.3 years shorter than
those without (p = 0.04). Seven/123 (5 %) of deaths were HHT related with a median age at death of 61.5 years (IQ
range 54.4–67.7 years).
Conclusion: Our study showed that the life expectancy of largely unscreened HHT patients was lower than people
without HHT. Female patients with Endoglin mutations were most strikingly at risk of premature death from
complications. These results emphasize the importance of referring patients with HHT for screening of organ
involvement and timely intervention to prevent complications.
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Hereditary Haemorrhagic Telangiectasia (HHT) is an
autosomal dominant disease with a prevalence of
approximately 1/5000 [1]. HHT is diagnosed genetically,
or clinically according to the Curaçao criteria [2]. Several
disease causing mutations are known but most fre-
quently patients are affected by mutations in the
Endoglin (ENG; MIM 131195) gene (HHT-I) [3] or* Correspondence: a.hosman@antoniusziekenhuis.nl
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601284) gene (HHT-II) [4]. The Curaçao criteria are
based on four clinical features: (i) the presence of
spontaneous, recurrent epistaxis, (ii) mucocutaneous
telangiectasia, (iii) visceral arteriovenous malforma-
tions (AVMs) and (iv) a first degree relative with
HHT. Patients are diagnosed with HHT if they fulfil
three out of four criteria. Two criteria results in a
“possible HHT” diagnosis.
Telangiectasia can manifest on oral mucosa, nasal
mucosa or on the face or fingers. Visceral AVMs mainly
occur in the lungs (pulmonary AVM), brain (cerebral
VM), gastro-intestinal tract and liver (hepatic VM) [5–7].
In patients with (possible) HHT, screening for organ
involvement is recommended to prevent complications.rticle is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
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from pulmonary AVMs or—more often—paradoxical
(sterile or septic) emboli which can lead to a stroke or
brain abscess [8–10]. Cerebral vascular malformations
(VMs) can lead to haemorrhagic stroke, and liver VMs
can lead to right congestive heart failure, portal hyperten-
sion, biliary necrosis or portosystemic encephalopathy
[11]. Frequent recurrent epistaxis and gastro-intestinal tel-
angiectasia, which mainly occur in the stomach and duo-
denum, can lead to iron deficiency anaemia [12].
To prevent complications and increase lifespan,
patients should be referred to specialized HHT Centres
for expert care and to screen for the presence of AVMs
[2]. Previous studies in a small number of patients
showed increased mortality in patients with HHT under
60 years of age [1, 13]. To study the life expectancy of
patients who did not receive treatment for their (asymp-
tomatic) AVMs, we evaluated the age of death of parents
of the current population referred to our clinics. The
aim was to determine whether life expectancy of
unscreened parents of our cohorts with HHT differed
from that of their non-HHT partner.
Methods
Population
The participating hospitals of this two-centre study are St.
Michael’s Hospital in Toronto, Canada and St. Antonius
Hospital in Nieuwegein, The Netherlands. Both hospitals
are internationally recognized HHT Centres. Two thou-
sand seven hundred and twenty-five patients screened for
HHT were selected in June 2008 from the Toronto and St
Antonius Hospital HHT Databases. The oldest generation
known to the clinic with a confirmed genetic or clinical
diagnosis of HHT, based on the Curaçao criteria, was
included. Respondents’ admissions were excluded if a sib-
ling had already returned a questionnaire on their parents
or where HHT had been ruled out in both parents after
screening in the clinic.
Study protocol
The study protocol was approved by the research ethics
boards of both participating hospitals (Medical Research
Ethics Committees United). All selected patients received
a letter with information on the study and a self-
administered questionnaire. Patients were asked to return
the questionnaire if both parents had deceased. If the
HHT parent was still alive, patients were asked to forward
the questionnaire to them with a request to complete it. If
no answer was received within 4 weeks, patients were
contacted by phone, by one of 2 well-trained interviewers
(EG and CE), to answer the same questions.
The health status in terms of HHT of the parents
of the participants was determined solely by the par-
ticipants' response and was not objectified. Howeverthe participants used in this study had their diagnosis
confirmed by the Curaçao criteria or genetic testing
and genealogies often show which side of the family
has HHT. Considering the hereditary nature of HHT
the questions on which parent was affected by HHT
allowed deduction of which parent was not affected
by HHT. Subsequently, parents could then be
assigned as HHT-patient or control. In case it was
unclear which parent had HHT, because of a de novo
mutation or when the HHT parent showed very little
symptoms or in case of unclear genealogy, the partici-
pant was excluded.
By using the parent not affected by HHT as control,
we assume the socioeconomic status of one set of
parents is comparable, making the control group and
HHT-group equal in socioeconomic status. The ques-
tionnaire queried the mortal status of both parents
and, if applicable, the cause of death. Parents with
HHT were divided in three groups: death definitely
HHT related, possibly HHT related and not HHT
related. Death secondary to pulmonary disease was
categorized as possibly HHT related unless caused by
pneumonia, emphysema, pulmonary embolism or tu-
berculosis; in these cases they were categorized as not
HHT related deaths. Death secondary to an infection
could be secondary to a paradoxical embolus leading
to an abscess or sepsis and was categorized as pos-
sibly HHT related unless influenza or meningitis were
the underlying causes; in these cases, they were cate-
gorized as not HHT related. Stroke was categorized
as possibly HHT related. If death was reported sec-
ondary to cardiac disease it was categorized as pos-
sibly HHT related unless caused by a cardiac arrest,
ruling it as not HHT related. To best interpret the
results, the “possibly HHT related” group was then
excluded from any further statistical analysis. The P-
value was derived from cox-regression based on com-
parison of each of the two subgroups with controls.
Furthermore, the questionnaire queried HHT related
symptoms in the HHT parent and asked whether this
parent had received treatment for these symptoms or
had been screened for HHT.
Statistical analysis
Data was analysed using IBM SPSS statistics 22 and
Microsoft Office Excel 2010. Survival data was analysed
using Cox regression and Kaplan-Meijer curves. Given
the inherent limitations of survey methodology, to assess
whether survival of the control group was realistic, cal-
culations from survival data reported for controls in the
current survey were compared to the survival data of
Dutch people in the national Dutch database (CBS stat-
Line) and Canadian people in the national Canadian
database (CANSIM).
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Of the 570 questionnaires sent out, 407 (71 %) were
completed, 9 (2 %) were returned because of an incor-
rect address and 154 (27 %) patients did not return the
questionnaire or respond to phone calls. Of the respon-
dents, 182 (45 %) were excluded for the following rea-
sons: incomplete response (24), parent without HHT
was still alive (73), neither parent was diagnosed with
HHT or had symptoms (the respondent was then
assumed to have a de novo mutation), parent had a low
grade phenotype or one of the parents was not the gen-
etic parent (52), or there were siblings among the
respondents (to avoid dataset duplicates) (33).
In total 225 (55 %) respondents were included, 85/
225 were from St. Michael’s Hospital and 140/225 were
from St. Antonius Hospital, providing information on
550 parents; 225 HHT parents, and 225 controls. Of
157 (69.8 %) HHT parents, the gene mutation causing
HHT was known. In the control group, males had
shorter lifespans (median age 74.0 years, IQ range
65.7–80.9) than females (median age 80.1 years, IQ
range 72.2–86.8), with a hazard ratio of 1.684 (95 % CI
1.284–2.208, p < 0.001) (Table 1).
This was as expected from the general Dutch and
Canadian population (CBS statLine, CANSIM). The
HHT group showed similar trends with respect to sex,
but the difference was not statistically significant (hazard
ratio 1.255, 95%CI 0.962–1.637, p = 0.096).
Parents with HHT had a significantly shorter lifespan
than parents without HHT. With a median age at death
of 73.3 years (IQ range 63.3, 81.7) in the HHT group
compared to a median age at death in controls of
76.6 years (IQ range 68.5, 83.2), HHT parents died
3.3 years earlier than controls (HR 1.252, 95 %CI 1.039–
1.508, p = 0.018) (Fig. 1). Further analysis shows this dif-









Total population 225 73.3 63.6 81
Endoglin 83 69.5 59.3 81
ACVRL1 74 76.0 67.1 82
Male 98 70.9 62.1 79
Endoglin 35 68.5 57.4 77
ACVRL1 31 73.4 66.1 81
Female 127 75.7 64.0 82
Endoglin 48 70.8 61.2 82
ACVRL1 43 77.0 68.4 83mutation. Parents with Endoglin mutations died signifi-
cantly earlier than controls (HR 1.338, IQ range 1.038–
1.723, p = 0.024) (Fig. 2). More strikingly, females with
an Endoglin mutation lived a median of 9.3 years shorter
than females without the mutation (HR 1.442, 95 % CI
1.017–2.043, p = 0.04) (Fig. 3). Males with an Endoglin
mutation seemed to live 5.5 years shorter than non-
HHT males, although this was not significant and may
be because the data were underpowered (HR 1.361, IQ
range 0.934–1.984, p = 0.109). By contrast, the lifespan of
parents with ACVRL1 mutations was not significantly dif-
ferent from those without (HR 1.101, 95 % CI 0.846–1.433,
p = 0.476) (Fig. 4).
Parents with HHT who had died because of an HHT
related complication had a lower median age at death
compared to those who had died from no HHT related
conditions (Table 2).
Of the seven parents who died from complications of
HHT, two had confirmed mutations in the Endoglin
gene and one had a mutation in the ACVRL1 gene. Four
(57 %) of them were women.
Screening and treatment of HHT parents was limited.
Only 5.3 % of parents with HHT were screened for the
presence of organ VMs and 8.9 % and 1.3 % were treated
for pulmonary AVMs and cerebral VMs respectively.
Discussion
This study illustrates that in an essentially unscreened
and untreated population of HHT patients who were the
parents of cohorts in our databases, the median life
expectancy is significantly lower than that of their non-
HHT partner. This is in alignment with a recent study
performed on 675, largely unscreened, HHT patients
showing a similar 3 year reduction in life expectancy,
mainly related to neurological and haemorrhagic compli-
cations [14]. More detailed analysis of our data showedgroup) and parents without HHT (control group), subdivided by
Control group
75 % no Median age
(years)
IQ range 25 %
(years)
IQ range 75 %
(years)
.7 225 76.6 68.5 83.2
.4
.9
.7 127 74.0 65.7 80.9
.8
.2
.5 98 80.1 72.2 86.8
.4
.1
Fig. 1 Kaplan-Meijer curve of HHT group versus control group. Log Rank: p = 0.018
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specified HHT cohort is largely attributable to reduced
life expectancy in women with a mutation in the Endo-
glin gene. Life expectancy of individuals with ACVRL 1
mutations did not seem to be affected.
Reduced life expectancy is more pronounced in female
with an Endoglin mutation, for reasons that are mainly
unclear although we can hypothesize. Possible reasons
might include the nature of the Endoglin phenotype,
which is associated with a higher prevalence of pul-
monary AVMs and cerebral VMs compared to the
ACVRL1 mutations. Cerebral VMs occur in approxi-
mately 8–16 % of patients with Endoglin phenotype as
opposed to 1–2 % of HHT-II patients with ACVRL1
mutation [15–18]. Pulmonary AVMs occur much more
frequently in patients with Endoglin mutations (62 %)
compared to patients with ACVRL1 mutations (10 %)
and complications may be life threatening [19]; Major
pulmonary AVM related complications include life-
threatening hemorrhage, as well as cerebral abscess (8 %)
and ischemic stroke (9 to 18 %) due to paradoxical emboli,
which can be fatal or leave patients severely physically
impaired [20, 21]. Fortunately, these complications canmostly be prevented through detection of pulmonary
AVM by screening and treatment [22].
Even though women with HHT have a higher risk of
life threatening pulmonary AVM-related complications
during pregnancy and possibly labour [23–26] this did
not appear to have a great impact on the study here: the
overall life expectancy curves of women with Endoglin
mutations only deviated in the 40–70 year range, and
not during the fertile years (Fig. 2). However, this could
be a result bias as women who died giving birth to their
first child would not have had offspring to submit data
for this study.
Seven parents whose death was definitely HHT related
had a lower mean age at death compared to the two
other groups. With present day standards of care, five of
these deaths secondary to pulmonary AVMs, i.e. pul-
monary haemorrhage and brain abscess, could have been
prevented by screening and treatment in advance.
There are limitations to the methodology used in this
study. The population included is biased, since it only
includes adult respondents. Patients with HHT who died
during childhood and in their twenties have been largely
missed, although these numbers are likely very low [13, 27].
Fig. 2 Kaplan-Meijer curve of unscreened Endoglin patients vs controls. Log Rank: p = 0.024
Fig. 3 Kaplan-Meijer curve of unscreened female Endoglin patients vs female controls. Log Rank: p = 0.038
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Fig. 4 Kaplan-Meijer curve of unscreened ACVLR1 patients vs controls. Log Rank: p = 0.476
Table 2 Causes of death of parents with HHT. P-value derived
from cox-regression based on comparison with controls
Cause of death HHT
related
Yes No
Number (%) 6 (5 %) 123 (95 %)





















de Gussem et al. Orphanet Journal of Rare Diseases  (2016) 11:46 Page 6 of 8Due to stringent inclusion criteria, parents without
prominent symptoms of HHT were also excluded, as
they might not have had HHT and their responding
child might have had a spontaneous mutation. How-
ever, these parents could have had a less evident
phenotype or died before becoming clearly symptom-
atic and therefore might have been incorrectly
excluded. Furthermore, studies on male HHT patients
specifically were underpowered. Underpowering of
these analyses can be explained by a smaller number
of male patients. This may be due to a female pre-
dominance resulting from a greater inclination of
Dutch female patients to be referred to an HHT
Centre for clinical evaluation [16]. Furthermore, we
excluded 73 participants of which the parent without
HHT was still alive. Of 53/73 (73 %) participants, the
deceased parent with HHT was male, this is consist-
ent with a generally lower life expectancy for men
compared to women. However, this led to a relatively
smaller male HHT-group included in the study.
We studied life expectancy in a largely unscreened
population in which only 5 % of the participants had
been examined in a specialized clinic. The goal of
current screening is to prevent HHT related complica-
tions and improve life expectancy in HHT patients.
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prove if patients are screened for visceral AVMs and
treated when necessary.
To improve life expectancy in patients with HHT or
suspected HHT, we strongly recommend referral to an
HHT Centre of Excellence for appropriate screening and
possible treatment of AVMs. International HHT guide-
lines recommend screening for pulmonary AVMs in all
people with HHT and also recommend referral to expert
centres for management of the various aspects of HHT.
Taking the hereditary nature of HHT in account, asymp-
tomatic family members should also be referred for
screening since clinical manifestations like epistaxis and
telangiectasia increase with age and might not be evident
initially. Asymptomatic AVMs can be present in the
young, potentially leading to life threatening complica-
tions. Furthermore, increasing awareness of HHT is essen-
tial in order to improve patient care because despite
greater awareness, HHT is still an under-diagnosed dis-
ease [28, 29].
Conclusion
In conclusion, our study confirms the findings of recent
literature that life expectancy in a largely unscreened
population with HHT is worse than in their non-HHT
partners [14], more specifically for patients with Endoglin
mutations and especially women. Because patients with
ACVRL1 mutations have a normal life expectancy, the
reduction in life expectancy in patients with an Endoglin
mutation is probably related to complications of untreated
pulmonary AVMs and cerebral VMs. We propose that life
expectancy in HHT can be normal if patients are screened
and both pulmonary AVMs and cerebral VMs are prop-
erly treated in a timely way. To prevent complications of
HHT, referral of patients with (suspected) HHT to an
HHT Centre of Excellence for screening, and if necessary
treatment, is highly recommended.
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